Register for free to listen to this article
Listen with Speechify
0:00
2:00
COLUMBIA, Md.—In Vitro ADMET Laboratories LLC (IVAL) and Taconic announced an agreement in late March under which IVAL will prepare cryopreserved hepatocytes derived from Taconic’s knockout and genetically humanized mouse models for use in preclinical drug development research. The resulting plateable cryopreserved hepatocytes will be a commercial product available from either company.
 
Using hepatocytes from Taconic’s translational mouse models, researchers can leverage in-vitro assays to facilitate experimental design and data analysis of in-vivo transgenic animal studies. The transgenic hepatocytes can also be used to conduct targeted in-vitro investigations to assess the contribution of specific proteins toward the absorption, distribution, metabolism, excretion, and toxicity characteristics of new compounds. Examples of the key proteins are drug transporters and drug metabolizing enzymes.
 
As the companies noted in their announcement, cryopreserved hepatocytes are “now considered the ‘gold standard’ for critical experiments in drug development including drug metabolism, drug-drug interactions, toxicity assessment and most recently, drug-transporter interactions,” and IVAL noted that it has extensive experience in isolating and cryopreserving human and animal hepatocytes. Reportedly, the company’s proprietary cryopreservation procedures successfully preserve many of the attributes of fresh hepatocytes that are often lost during the cryopreservation process.
 
“We are extremely enthusiastic about this alliance that leverages the unparalleled hepatocyte technologies of IVAL and the world’s leading transgenic technologies of Taconic,” stated Dr. Albert P. Li, President and CEO of IVAL. “The transgenic hepatocytes will complement our current portfolio of hepatocyte products and greatly facilitate scientific research, especially in drug discovery and development.”
 
“The collaboration agreement with IVAL is Taconic’s most recent step to expand its tADMET portfolio, a unique collection of in-vivo and in-vitro tools applied in preclinical DMPK and safety testing,” said Todd Little, Taconic president and CEO. “The commercial supply of hepatocytes derived from Taconic’s proprietary genetically-engineered tADMET mouse models is an ideal complement to our toolbox of genetic and tissue humanized rodent models.”

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue